What is claimed is:


1. A conjugate of formula T-L-A in which:

   T is a ligand that targets prostate-specific membrane antigen (PSMA),


   L is a linker, and

   A comprises an inhibitor of a DNA repair enzyme, wherein the inhibitor of a DNA repair enzyme is a protein arginine methyltransferase 5 (PRMT5) inhibitor, an ataxia-telangiectasia mutated (ATM) inhibitor or a DNA protein kinase (DNA-PK) inhibitor.

2. The conjugate of claim 1, wherein T is:




DUPA
IC50 = 47 nM
Ki = 8 nM




IC50 = 10 uM


IC50 = 2 uM




IC50 = 700 nM




IC50 = 0.3 nM




MUPA
IC50 = 6.9 nM




IC50 = 185 nM




IC50 = 29 nM



IC50 = 560 nM




IC50 = 1 nM




Ki = 0.9 nM

or




IC50 = 0.5 nM



IC50 = 2 nM

.

3. The conjugate of claim 1, wherein T is:



, in which R^1 and R^2 are independently selected from hydrogen, carboxylic acid, which is optionally substituted, malonic acid, succinic acid, glutamic acid, and adipic acid.

4. The conjugate of any one of claims 1 to 3, wherein L comprises a chain of atoms from about 5 Å to about 45 Å in length.

5. The conjugate of any one of claims 1 to 4, wherein L comprises a polyoligoethylene glycoln (POEGn), a polyethylene glycoln (PEGn), or a mixture thereof, wherein n = 1-36.


6. The conjugate of claim 1, wherein the PRMT5 inhibitor comprises a radical of JNJ-64619178 or a radical of GSK3326595.

7. The conjugate of claim 1, wherein the ATM inhibitor comprises a radical of AZD0156.

8. The conjugate of claim 1, wherein the DNA-PK inhibitor comprises a radical of Nedisertib, AZD7648, KU57748, Torin 2, PI-103, NU7026, Samotolisib, PIK 90, CC-115, PIK-75 hydrochloride, VX-984, KU-0060648, BAY-8400, DNA-PK-IN-2, DNA-PK-IN-1, DNA-PK-IN-4, DNA-PK-IN-5, DNA-PK-IN-6, XRD-0394, NU5455, STL127705, PI-103 hydrochloride, LTURM34, ZL-2201 free base, DNA-PK-IN-14, DNA-PK-IN-10, DNA-PK-IN-11 or DNA-PK-IN-13.


9. The conjugate of any one of claims 1 to 8 further comprising an albumin binding group.

10. The conjugate of claim 9, wherein the albumin binding group is of the formula:




.


11. A conjugate of the formula:




,



,



or



.

12. A conjugate of formula T-L-(X)A in which:

T is a ligand that targets prostate-specific membrane antigen (PSMA),


L is a linker,

A comprises an inhibitor of a DNA repair enzyme, wherein the inhibitor of a DNA repair enzyme is a protein arginine methyltransferase 5 (PRMT5) inhibitor, an ataxia-telangiectasia mutated (ATM) inhibitor or a DNA protein kinase (DNA-PK) inhibitor; and

X is a radiotherapeutic or radioimaging agent.

13. The conjugate of claim 12, further comprising an albumin binding group.

14. The conjugate of claim 13, wherein the albumin binding group is of the formula:



15. A pharmaceutical composition comprising a conjugate of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a conjugate of any one of claims 12 to 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

17. Use of a conjugate of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 15, in the manufacture of a medicament for treating a patient for prostate cancer or metastasis thereof with radiotherapy.

18. The use of claim 17, wherein the medicament is to be administered according to a treatment comprising administering a conjugate of the formula T-L-X or a pharmaceutically acceptable salt thereof to the patient before or after administering a conjugate of formula T-L-A or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to the patient, in which:

T is a ligand that targets prostate-specific membrane antigen (PSMA),

L is a linker,

X is a radiotherapeutic or radioimaging agent; and

A comprises an inhibitor of a DNA repair enzyme, wherein the inhibitor of a DNA repair enzyme is a protein arginine methyltransferase 5 (PRMT5) inhibitor, an ataxia-telangiectasia mutated (ATM) inhibitor or a DNA protein kinase (DNA-PK) inhibitor.

19. The use of claim 18, wherein the treatment further comprises administering to the patient an immune checkpoint inhibitor optionally selected from the group consisting of an inhibitor of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), an inhibitor of programmed cell death protein 1 (PD-1), and an inhibitor of programmed cell death ligand 1 (PD-L1).

20. Use of a conjugate of any one of claims 12 to 14 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 16, in the manufacture of a medicament for treating a patient for prostate cancer or metastasis thereof with radiotherapy.